# Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use

> **NCT02121535** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** T80/A5 mg FDC tablet
- **DRUG:** T80/A5 mg FDC tablet
- **DRUG:** H12.5 mg tablet
- **DRUG:** T80/A5/H12.5 ng FDC tablet
- **DRUG:** H12.5 mf tablet
- **DRUG:** T80/A5/H12.5 mg FDC tablet

## Key facts

- **NCT ID:** NCT02121535
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02121535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02121535, "Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02121535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*